If you have been reading about angiotensin IV and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-12. Numbers and descriptions here follow the published literature rather than marketing material.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
== Treatments == Treatments differ according to the type of amyloidosis present. The majority of treatment is aimed at preserving heart function and treating heart failure symptoms. Loop diuretics are often used for fluid overload symptoms due to heart failure. Light chain (AL-CM) Treatment: Since the cause of this subtype of cardiac amyloidosis is the excessive production of free light chains, the major goal of treatment is the reduction in concentration of light chains. For light-chain amyloidosis, the use of FLC assays and NT-proBNP levels can be used to monitor the progression of amyloidosis and any response to treatments. One of the major routes to decrease the production of these excess light chains is to kill the abnormal cells that are producing them. Chemotherapeutic agents such as melphalan or bortezomib can be used to kill off the abnormal cell line that is producing the free light chains. Following chemotherapy, a bone marrow transplant can be utilized to restore the normal cell lines. There are newer medications (ixazomib, carfilzomib, daratumumab, elotuzumab) under research for the treatment of multiple myeloma that can help to decrease the production of free light chains. New data suggests that orthotopic heart transplant followed by melphalan and stem cell transplant produces results similar to non cardiac amyloidosis indicated heart transplant.
2,5-Dimethoxyamphetamine (2,5-DMA), also known as DMA-4 or as DOH, is a psychoactive drug of the phenethylamine and amphetamine families. It is one of the dimethoxyamphetamine (DMA) series of positional isomers. The drug is notable in being the parent compound of the DOx (4-substituted-2,5-dimethoxyamphetamine) series of psychedelic drugs. It is taken orally.
Beta decay does not change the number (A) of nucleons in the nucleus, but changes only its charge Z. Thus the set of all nuclides with the same A can be introduced; these isobaric nuclides may turn into each other via beta decay. For a given A there is one that is most stable. It is said to be beta stable, because it presents a local minimum of the mass excess: if such a nucleus has (A, Z) numbers, the neighbour nuclei (A, Z−1) and (A, Z+1) have higher mass excess and can beta decay into (A, Z), but not vice versa. For all odd mass numbers A, there is only one known beta-stable isobar. For even A, there are up to three different beta-stable isobars experimentally known; for example, 12450Sn, 12452Te, and 12454Xe are all beta-stable. There are about 350 known beta-decay stable nuclides.
== Animal welfare == Taco Bell is subject to the animal welfare standards of its parent company, Yum! Brands. In 2016, Taco Bell stopped sourcing eggs from egg-laying hens raised in battery cages in their US restaurants. In 2024, Taco Bell announced that it would publish benchmarks on moving away from gestation crates in pork production by the end of 2024. However, no such benchmarks were published that year.
== External links == IUPHAR GPCR Database and Ion Channels Compendium Archived 2019-03-23 at the Wayback Machine Human plasma membrane receptome Archived 2019-09-15 at the Wayback Machine Cell+surface+receptors at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Sources: en.wikipedia.org
Since radioactive decay is exponential with a constant probability, each process could as easily be described with a different constant time period that (for example) gave its "(1/3)-life" (how long until only 1/3 is left) or "(1/10)-life" (a time period until only 10% is left), and so on. Thus, the choice of τ and t1/2 for marker-times, are only for convenience, and from convention. They reflect a fundamental principle only in so much as they show that the same proportion of a given radioactive substance will decay, during any time-period that one chooses. Mathematically, the nth life for the above situation would be found in the same way as above—by setting N = N0/n, t = T1/n and substituting into the decay solution to obtain
== Effects == The spectrum of effects of hormone therapy in transfeminine people depend on the specific medications and dosages used. In any case, the main effects of hormone therapy in transfeminine people are feminization and demasculinization, and are as follows:
=== L’Art islamique en Orient I, II and III (Islamic Art in the East I, II and III) === In 1922, he worked on publishing the first book of his Islamic art reproductions, Alttürkishe Keramik or L’Art islamique en Orient – Première Partie (Islamic Art in the East – Part One, published in French). In 1923, with the financial backing of American millionaire Charles Crane, he commissioned the printing of L’Art islamique en Orient, Deuxième Partie (Fragments d’architecture religieuse et civile) (Islamic Art in the East, Part Two (Fragments of Religious and Civil Architecture)) and L’Art islamique en Orient, Troisième Partie (Islamic Art in the East, Part Three), published in French in Prague by the Printing House Schulz.
Tasmanian oak is a native Australian hardwood produced by any of three trees, Eucalyptus regnans, Eucalyptus obliqua or Eucalyptus delegatensis, when it is sourced from the Australian state of Tasmania. Despite the common name "oak", none of the species are in the genus Quercus or the oak family Fagaceae. The hardwood timber is light-coloured, ranging from straw to light reddish brown. It is used in construction, including panelling and flooring, for furniture, and also for reconstituted board and high quality paper. When sourced from Victoria, the wood of Eucalyptus regnans and Eucalyptus delegatensis is called Victorian ash. The species are also widely known by their common names. Eucalyptus obliqua is known as stringybark or messmate, Eucalyptus regnans is known as mountain ash, and the closely related Eucalyptus delegatensis is known as alpine ash or woollybutt.
Sources: en.wikipedia.org
Corin converts the atrial natriuretic peptide (ANP) precursor, pro-ANP, to mature ANP, a cardiac hormone that regulates salt-water balance and blood pressure. In mice, corin deficiency prevents pro-ANP processing and causes salt-sensitive hypertension. Corin may also function as a pro-brain-type natriuretic peptide convertase. Corin-mediated ANP production in the pregnant uterus promotes spiral artery remodeling and trophoblast invasion. CORIN mutations have been reported in patients with preeclampsia. In mice, corin functions in the dermal papilla to regulate coat color in an Agouti-dependent pathway.
== Medical uses == Chlordiazepoxide hydrochloride is indicated for the short-term (2–4 weeks) treatment of anxiety that is severe and disabling or subjects a person to uncomfortable distress. It is also indicated as a treatment for the management of acute alcohol withdrawal syndrome. Chlordiazepoxide hydrochloride may be used by chronic benzodiazepine users to discontinue benzodiazepine use. The long half-life means that the patient’s final dose will last several days, making the likelihood of withdrawal symptoms lower. Tapering can last months to years. It is sometimes prescribed to ease symptoms of irritable bowel syndrome (IBS) when combined with clidinium bromide in the fixed dose medication, Librax.
in the above equation modulo ln(2)) of the parent and daughter, respectively, and BR is the branching ratio. In transient equilibrium, the Bateman equation cannot be simplified by assuming the daughter's half-life is negligible compared to the parent's half-life. The ratio of daughter-to-parent activity is given by:
Unione Sportiva Milanese was founded on 16 January 1902 as a multi-sports club, for compete in different disciplines, by Ambrogio Ferrario, Romolo Buni and Gilbert Marley at the Caffè Verdi in Porta Nuova in Milan. In the spring of 1904 the football section was established on the initiative of some footballers and gymnasts who left first A.C. Milan and then Mediolanum (among of which Umberto Meazza), while the affiliation to the Italian Football Federation (FIF), the current FIGC, took place in 1905. The shirt was black and white checked, with white shorts and black socks. Red and white were the colors of the second jersey. By virtue of this choice, against the current compared to the norm of the others teams, were nicknamed "Gli Scacchi" (the chessmen). At the end of the 1927-1928 championship, U.S. Milanese was automatically promoted to the National Division but was also forced by the fascist regime to merge with the Internazionale in the new Società Sportiva Ambrosiana, whose management was appointed Ernesto Torrusio, president of U.S. Milanese at the time, in favor of the fact that the registration number used to register for the championship was precisely that of U.S. Milanese. For two years the S.S. Ambrosiana celebrated the U.S. Milanese using its historic logo and the black and white checkered collar: S.S. Ambrosiana won the Italian football championship in 1929/30 season. 1932 saw the end of the merger with Internazionale and the reconstitution of U.S. Milanese, which was reborn only as a sports club without the football section. In 1945 U.S.
=== Cognitive problems ("fibro fog") === Many people with fibromyalgia experience cognitive problems often known as "fibro fog". The CDC and the American Pain Society recognize these problems as a major feature of fibromyalgia. About 75% of people with fibromyalgia report significant problems with concentration, memory, and multitasking. A 2018 meta-analysis found that the largest differences between people with fibromyalgia and healthy subjects were in inhibitory control, memory, and processing speed. A 2023 scoping review grouped effects into subjective cognitive dysfunction, perceived variability, changes in functional activities, and participation limitations. A 2017 review found that the neuropsychological mechanisms underlying brain fog may be similar to those in isolated functional cognitive disorders. One hypothesis is that chronic pain in fibromyalgia compromises attention systems, resulting in cognitive problems.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.